27 citations
,
January 1984 in “Pharmacology & Therapeutics” Antiandrogens have important biological effects, but more research is needed to understand them fully and compare their effectiveness and side effects to other treatments.
18 citations
,
April 2001 in “Bioorganic & Medicinal Chemistry Letters” The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.
9 citations
,
September 2014 in “Cancer Epidemiology, Biomarkers & Prevention” Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.
6 citations
,
November 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists created iodinated arylhydantoins and arylthiohydantoins that could potentially be used for imaging prostate cancer. Some versions with specific side-chains showed high potential for this use.
April 2022 in “Authorea (Authorea)” CT scans can find serious prostate cancer even when PSA levels are low.
9 citations
,
March 1991 in “Endocrinology” Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
1 citations
,
January 2022 in “European Journal of Pharmacology” Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
24 citations
,
April 2014 in “Oncotarget” Minoxidil can reduce functions related to androgen receptors.
22 citations
,
January 2017 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” A new method accurately measures nine specific hormones in human blood.
218 citations
,
December 2011 in “Advances in Urology” The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.
20 citations
,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
14 citations
,
November 2008 in “Expert opinion on drug metabolism & toxicology” Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.
1 citations
,
January 2009 in “X-ray Structure Analysis Online” A new compound was made that might help treat diseases related to male hormones.
101 citations
,
April 1994 in “Baillière's clinical endocrinology and metabolism” 5α-reductase is essential for male sexual development and its inhibitors have potential in treating various conditions related to hormone action.
403 citations
,
November 2005 in “Journal of Endocrinology” Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.
97 citations
,
November 1986 in “Journal of Steroid Biochemistry” Antiandrogens affect androgen-dependent body functions and are used for various medical conditions, with some risks like fetus feminization, but new forms like 17α-propylmesterolone show promise for acne without systemic effects.
7 citations
,
August 2019 in “Bioorganic & medicinal chemistry” Analog 23 is a promising compound for prostate cancer treatment.
April 2003 in “Experimental Dermatology” The workshop highlighted the genetic links and psychological impacts of hair loss and skin disorders.
December 1998 in “Acta Crystallographica Section C-crystal Structure Communications” A new compound with strong antiandrogenic effects was found, potentially useful for treating conditions like acne and prostate cancer.
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
April 2012 in “The Journal of Urology” Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.
59 citations
,
April 2016 in “Breast Cancer Research and Treatment” Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.
April 2012 in “The Journal of Urology” More prostate biopsies increase the chance of finding cancers that may not need treatment.
3 citations
,
December 2016 in “Canadian Urological Association journal” Men with more advanced male pattern baldness have a higher risk of prostate cancer and more severe disease.
April 2012 in “The Journal of Urology” Male pattern baldness may predict prostate cancer risk.
20 citations
,
May 2011 in “Cancer Biology & Therapy” Finasteride may improve prostate cancer treatment outcomes.
August 2025 in “Fabad Journal of Pharmaceutical Sciences” Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
June 2012 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Six new risk spots for early hair loss were found, which also link to Parkinson's disease and lower fertility. Two genes, FOXA2 and HDAC4, could be new treatment targets. Hair loss might also be connected to heart disease, metabolic syndrome, and prostate cancer.
2 citations
,
June 2022 in “Molecules” Connarus semidecandrus Jack extract promotes hair growth and thickness, reduces prostate cancer cell growth, and could potentially be used as a treatment for hair loss.
21 citations
,
February 2021 in “Frontiers in Endocrinology” Hormones affect prostate health and disease, with certain hormone imbalances linked to prostate cancer and benign prostatic hyperplasia.